Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data
Chao Zhu, Sandra Vukusic, Tomáš Kalinčík, Guillaume Mathey et autres
BACKGROUND: Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. METHODS: We conducted an observational cohort study emulating a target trial …
au, fr, cz, tr, hr, ir, es, nl, mx, be, ca, it, kw, si, mq (code pays fourni par la source)
0 citations
Journal of Neurology Neurosurgery & Psychiatry